Maat Pharma
MAAT.PA is a biotechnology company focused on pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of innovative therapies.
Business. MAAT.PA is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in France and is primarily listed on the Euronext Paris exchange under the ticker MAAT.PA. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
6 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
MAAT.PA is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in France and is primarily listed on the Euronext Paris exchange under the ticker MAAT.PA. Specific details regarding its operating segments and geographic revenue mix are not available.
MAAT.PA's capital structure is highly leveraged, with a debt-to-equity ratio of 9.69, indicating significant reliance on debt financing. The company's liquidity position is moderate, with a current ratio of 1.94, but its operating cash flow is negative at -15.72 million EUR, and free cash flow is -30.07 million EUR, suggesting ongoing cash burn. The price-to-book ratio of 28.08 indicates that the market is valuing the company's equity at a premium relative to its book value, despite a negative return on equity of -17.27%.
Profitability metrics show a stark contrast to industry norms, with a return on assets of -0.70% and a return on equity of -17.27%, both significantly below the typical performance of companies in the biotechnology and medical research sector. The company's operating income is -29.73 million EUR, and net income is -31.06 million EUR, reflecting substantial operational losses.
Geographically, MAAT.PA's revenue is not segmented by region in the available data, but the company's exposure to the European market is implied by the EUR financial reporting and its listing on the Paris stock exchange. There is no disclosed segmental breakdown of revenue, which limits visibility into the diversification of its business.
The company's growth trajectory is constrained by its current financial performance, with no specific revenue growth projections provided in the available data. The negative operating and net income figures suggest that the company is not currently generating sustainable earnings.
Risk factors include a high debt load and negative net cash position, which could limit the company's flexibility and increase financial distress risk. The risk assessment indicates a low probability of dilution, but the company's capital structure and liquidity position remain a concern.
Recent events include the publication of the latest financial data, which shows continued losses and a high debt-to-equity ratio. Analysts have provided a range of price targets, with a mean of 15.50 EUR and a median of 16.00 EUR, indicating a generally positive outlook despite the company's current financial challenges.
- MAAT.PA is a biotechnology company with a high debt-to-equity ratio of 9.69, indicating significant leverage.
- The company's return on equity is -17.27%, and return on assets is -0.70%, both well below industry norms.
- MAAT.PA's liquidity position is moderate, with a current ratio of 1.94, but it is experiencing negative operating and free cash flows.
- Analysts have provided a range of price targets, with a mean of 15.50 EUR and a median of 16.00 EUR, suggesting a generally positive outlook despite current financial challenges.
- "margin_outlook_rationale": "The company's operating and net margins are negative, indicating a lack of profitability and potential margin compression.",
- "rd_outlook_rationale": "No specific R&D outlook is provided, but the company's focus on biotechnology suggests ongoing investment in research and development.",
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,87 |
| Revenue | —no estimate | —no estimate | 15,0M EUR |
| Operating income | —no estimate | —no estimate | -28,5M EUR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- MAAT.PA Market data — financials · 2026-05-28
- Maat Pharma SA Market data — analyst estimates · 2026-05-28